logo
Share SHARE
FONT-SIZE Plus   Neg

Keryx Says Perifosine X-PECT Phase 3 Trial Failed To Meet Primary Goal

Keryx Biopharmaceuticals, Inc. (KERX: Quote) said the Phase 3 "X-PECT", or Xeloda + Perifosine Evaluation in Colorectal cancer Treatment, clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer failed to achieve the primary endpoint of improving overall survival versus capecitabine + placebo.

The company noted that 468 patients at sixty-five U.S. sites participated in the study.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are all extremely disappointed with the results of the study...We will evaluate whether our Phase 3 study of Perifosine in relapsed/refractory multiple myeloma will continue as planned.

With approximately $31 million in cash as of March 31, 2012, and a well-controlled burn rate, we plan to focus our resources on the pending completion of the Zerenex (ferric citrate) long-term Phase 3 study for end stage renal disease (ESRD) patients with hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug Application (NDA) filing for Zerenex which will hopefully follow shortly thereafter."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The last moments of the doomed Germanwings plane, that was deliberately hit to the Alps, was recorded in a mobile phone, German newspaper Bild and French Magazine Paris Match reported. The video is presumed to be taken from the cabin, using a mobile device. The investigators recovered the memory card from the crash site, though the mobile was destroyed completely. However, there is no official con US Steel Corp. (X) Tuesday said it will "adjust operations" and temporarily idle a part of its Minntac plant in Mt. Iron, Minnesota, effective June 1. According to reports, the move would see about 700 employees laid off. The company said the decision was due to its current inventory levels and ongoing... Hewlett-Packard Co. (HPQ) has filed a lawsuit against Michael Lynch, the co-founder of Autonomy Corp., and its former Financial Chief Sushovan Hussain for a whopping $5.1 billion alleging that the executives misrepresented the financial situation of Autonomy. An HP's spokeswoman confirmed that the...
comments powered by Disqus
RELATED NEWS
Trade KERX now with 
Follow RTT